Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Sep;103(9):1422-1432.
doi: 10.3324/haematol.2018.191288. Epub 2018 Jul 26.

Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA)

Sara Bringhen  1 , Alberto Milan  2 , Claudio Ferri  3 , Ralph Wäsch  4 , Francesca Gay  5 , Alessandra Larocca  5 , Marco Salvini  5 , Evangelos Terpos  6 , Hartmut Goldschmidt  7 , Michele Cavo  8 , Maria Teresa Petrucci  9 , Heinz Ludwig  10 , Holger W Auner  11 , Jo Caers  12 , Martin Gramatzki  13 , Mario Boccadoro  5 , Hermann Einsele  14 , Pieter Sonneveld  15 , Monika Engelhardt  4 ; European Hematology Association, the European Myeloma Network and the Italian Society of Arterial Hypertension
Affiliations
Review

Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA)

Sara Bringhen et al. Haematologica. 2018 Sep.

Abstract

Cardiovascular disease in patients with multiple myeloma may derive from factors unrelated to the disease (age, diabetes, dyslipidemia, obesity, prior cardiovascular diseases), related to the disease (cardiac AL-amyloidosis, hyperviscosity, high-output failure, arteriovenous shunting, anemia, renal dysfunction) and/or related to anti-myeloma treatment (anthracyclines, corticosteroids, alkylating agents, immunomodulatory drugs, proteasome inhibitors). Good knowledge of cardiovascular events, effective dose reductions, prevention and management of early and late cardiovascular side effects of chemotherapeutic agents are essential in current clinical practice. Myeloma experts are obliged to carefully balance the efficacy and toxicity of drugs for each individual patient. This review summarizes current data and novel insights into cardiovascular adverse events of today's anti-myeloma treatment, focusing on carfilzomib, as a starting point for developing consensus recommendations on preventing and managing cardiovascular side effects in patients with multiple myeloma.

PubMed Disclaimer

References

    1. Moreau P, San Miguel J, Ludwig H, et al. , on behalf of the ESMO Guidelines Working Group. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(6): vi133–vi137. - PubMed
    1. National Cancer Institute. SEER Stat Fact Sheets: Myeloma. Available at: www.seer.cancer.gov/statfacts/html/mulmy.html. Accessed March 2016.
    1. Kistler KD, Rajangam K, Faich G, Lanes S. Cardiac event rates in patients with newly diagnosed and relapsed multiple myeloma in US clinical practice. Blood. 2012;102(21):2916.
    1. WHO 2016 Fact sheets-media centre. http://www.who.int/mediacentre/factsheets/fs317/en/.
    1. WHO 2016 fact files. http://www.who.int/features/factfiles/ageing/ageing_facts/en/.

MeSH terms